+Compare
EVLO
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
9.09M

EVLO Evelo Biosciences Forecast, Technical & Fundamental Analysis

a developer of oncobiotic therapeutics for cancer

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for EVLO with price predictions
07:00 PM EST Nov 26, 2023

EVLO in -30.98% downward trend, sliding for three consecutive days on November 27, 2023

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where EVLO declined for three days, in of 350 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

EVLO broke above its upper Bollinger Band on November 16, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for EVLO entered a downward trend on November 13, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where EVLO's RSI Indicator exited the oversold zone, of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 63 cases where EVLO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 15, 2023. You may want to consider a long position or call options on EVLO as a result. In of 72 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for EVLO just turned positive on November 01, 2023. Looking at past instances where EVLO's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EVLO advanced for three days, in of 258 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.511) is normal, around the industry mean (20.463). P/E Ratio (0.000) is within average values for comparable stocks, (137.276). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.954). Dividend Yield (0.000) settles around the average of (0.036) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (329.780).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. EVLO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 467.58B. NVO holds the highest valuation in this group at 467.58B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 0%. For the same Industry, the average monthly price growth was 31%, and the average quarterly price growth was 7%. SEPSF experienced the highest price growth at 145%, while TMBR experienced the biggest fall at -77%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -34%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was 1%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 59
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: -5 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

EVLO is expected to report earnings to fall 41.30% to -270 cents per share on August 03

Evelo Biosciences EVLO Stock Earnings Reports
Q2'23
Est.
$-2.70
Q1'23
Missed
by $4.42
Q4'22
Beat
by $0.07
Q3'22
Beat
by $0.04
Q2'22
Beat
by $0.01
The last earnings report on June 01 showed earnings per share of -459 cents, missing the estimate of -18 cents. With 1.31M shares outstanding, the current market capitalization sits at 9.09M.
A.I. Advisor
published General Information

General Information

a developer of oncobiotic therapeutics for cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
620 Memorial Drive
Phone
+1 617 577-0300
Employees
66
Web
https://www.evelobio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TENX0.400.04
+10.02%
Tenax Therapeutics
WERN39.670.09
+0.23%
Werner Enterprises
GGG81.21-0.27
-0.33%
Graco
IMAB1.53-0.07
-4.38%
I-MAB
BLFS13.44-0.64
-4.55%
BioLife Solutions

EVLO and

Correlation & Price change

A.I.dvisor indicates that over the last year, EVLO has been loosely correlated with MDGL. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if EVLO jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVLO
1D Price
Change %
EVLO100%
-12.52%
MDGL - EVLO
34%
Loosely correlated
+0.89%
FDMT - EVLO
29%
Poorly correlated
+0.24%
EIGR - EVLO
27%
Poorly correlated
-5.28%
AVRO - EVLO
27%
Poorly correlated
-0.79%
ICPT - EVLO
27%
Poorly correlated
N/A
More

Groups containing EVLO

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVLO
1D Price
Change %
EVLO100%
-12.52%
therapy
(undefined stocks)
15%
Poorly correlated
-0.81%
cancer
(undefined stocks)
10%
Poorly correlated
-1.56%
pharmaceuticals
(undefined stocks)
7%
Poorly correlated
-0.71%